Affordable access to innovative cancer medicines — don’t forget the prices

Narcyz Ghinea and Wendy Lipworth
Med J Aust 2016; 204 (6): . || doi: 10.5694/mja15.01309
Published online: 4 April 2016

Efforts to improve access to cancer medicines should not overlook exorbitant prices

On 17 September 2015, the much anticipated Senate report on the Availability of new, innovative and specialist cancer drugs in Australia was released.1 The inquiry preceding the report, which was triggered by concerns about inadequate and inequitable access to cancer medicines, had attracted over 200 submissions from doctors, patients, patient advocacy groups and government decision makers.

  • Centre for Values, Ethics and the Law in Medicine, University of Sydney, Sydney, NSW



This work is funded by a National Health and Medical Research Council grant.

Competing interests:

Wendy Lipworth is affiliated with the Drug Information Association.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.